Group One Trading
OCUL icon

Group One Trading’s Ocular Therapeutix OCUL Stock Holding History

Group One Trading’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$614K Sell
72,500
-7,600
-9% -$72.4K ﹤0.01% 3161
2025
Q4 		$972K Sell
80,100
-2,100
-3% -$25.5K ﹤0.01% 2916
2025
Q3 		$961K Buy
82,200
+24,200
+42% +$289K ﹤0.01% 3074
2025
Q2 		$538K Sell
58,000
-13,100
-18% -$103K ﹤0.01% 3339
2025
Q1 		$521K Buy
71,100
+19,900
+39% +$153K ﹤0.01% 3042
2024
Q4 		$437K Sell
51,200
-47,600
-48% -$464K ﹤0.01% 3285
2024
Q3 		$860K Sell
98,800
-109,800
-53% -$905K ﹤0.01% 2432
2024
Q2 		$1.43M Sell
208,600
-457,700
-69% -$2.83M 0.01% 1719
2024
Q1 		$6.06M Buy
666,300
+608,000
+1,043% +$4.31M 0.02% 710
2023
Q4 		$260K Buy
58,300
+23,200
+66% +$68.6K ﹤0.01% 3624
2023
Q3 		$110K Buy
35,100
+5,100
+17% +$20.9K ﹤0.01% 4362
2023
Q2 		$155K Buy
30,000
+29,500
+5,900% +$175K ﹤0.01% 4200
2023
Q1 		$2.63K Sell
500
-3,100
-86% -$14.7K ﹤0.01% 6539
2022
Q4 		$10.1K Sell
3,600
-200
-5% -$662 ﹤0.01% 6028
2022
Q3 		$16K Buy
+3,800
New +$19.1K ﹤0.01% 6224
2022
Q2 		– Sell
-7,600
Closed -$38K – 8291
2022
Q1 		$38K Sell
7,600
-8,500
-53% -$47.1K ﹤0.01% 6317
2021
Q4 		$112K Hold
16,100
– – ﹤0.01% 5639
2021
Q3 		$161K Sell
16,100
-67,300
-81% -$756K ﹤0.01% 5396
2021
Q2 		$1.18M Buy
83,400
+21,900
+36% +$333K ﹤0.01% 3218
2021
Q1 		$1.01M Buy
61,500
+28,000
+84% +$539K ﹤0.01% 3220
2020
Q4 		$693K Buy
33,500
+31,500
+1,575% +$468K ﹤0.01% 2980
2020
Q3 		$15K Sell
2,000
-15,100
-88% -$125K ﹤0.01% 5265
2020
Q2 		$142K Buy
17,100
+7,200
+73% +$47.7K ﹤0.01% 3649
2020
Q1 		$49K Buy
9,900
+2,200
+29% +$10.9K ﹤0.01% 3730
2019
Q4 		$30K Sell
7,700
-3,300
-30% -$11.5K ﹤0.01% 4228
2019
Q3 		$33K Buy
11,000
+7,500
+214% +$33.5K ﹤0.01% 4172
2019
Q2 		$15K Buy
3,500
+1,500
+75% +$5.55K ﹤0.01% 4282
2019
Q1 		$8K Sell
2,000
-2,000
-50% -$8.04K ﹤0.01% 4339
2018
Q4 		$16K Sell
4,000
-9,800
-71% -$54K ﹤0.01% 4114
2018
Q3 		$95K Buy
13,800
+6,300
+84% +$39.5K ﹤0.01% 3576
2018
Q2 		$51K Buy
7,500
+100
+1% +$687 ﹤0.01% 3941
2018
Q1 		$48K Sell
7,400
-5,200
-41% -$29.3K ﹤0.01% 3683
2017
Q4 		$56K Buy
12,600
+10,300
+448% +$52.6K ﹤0.01% 3668
2017
Q3 		$14K Sell
2,300
-15,800
-87% -$102K ﹤0.01% 4195
2017
Q2 		$168K Buy
18,100
+13,100
+262% +$127K ﹤0.01% 2769
2017
Q1 		$46K Buy
+5,000
New +$41.6K ﹤0.01% 3464
2016
Q4 		– Sell
-4,200
Closed -$29K – 4702
2016
Q3 		$29K Buy
+4,200
New +$25.6K ﹤0.01% 3630
2016
Q2 		– Sell
-1,800
Closed -$17K – 4845
2016
Q1 		$17K Hold
1,800
– – ﹤0.01% 3823
2015
Q4 		$17K Sell
1,800
-5,000
-74% -$54K ﹤0.01% 3991
2015
Q3 		$96K Buy
+6,800
New +$137K ﹤0.01% 3066

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Group One Trading's OCUL Position: Q3 2025 in Review

Group One Trading sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 11,950 shares — an estimated $143K sold.

Group One Trading first reported a position in OCUL in Q3 2015 and held it in 27 quarters. The position peaked at $3.4M in Q1 2024. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • Group One Trading reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 11,950 Ocular Therapeutix shares in Q3 2025, an estimated $143K.
  • Group One Trading first reported a position in Ocular Therapeutix in Q3 2015 and held it in 27 quarters.
  • Group One Trading's Ocular Therapeutix position peaked at $3.4M in Q1 2024.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.